Increase in demand for innovative drugs and therapies at affordable prices is a leading factor driving the pharmerging market value. Insurance companies located in pharmerging countries offer comprehensive policies to reduce the overheads of patients.
Growth in prevalence of chronic diseases translates into the need for insurance cover to avail medicines and broader modes of treatment as per requirement. Increase in awareness about the importance of early detection of diseases is also fueling pharmerging industry revenue.
Companies operating in the global pharmerging market are providing generic medicines in larger quantities in order to reach out to the underprivileged population in developing economies.
Regulatory bodies are also expediting the approval process for these drugs. Asia Pacific, primarily with the assistance from China and Japan, is projected to move out of the ‘pharmergy’ tag during the forecast period, with exponential growth in the pharmaceuticals sector.
Pharmerging refers to a group of countries that are not well-placed in the pharmaceuticals sector, but are poised to witness speedy growth in the future. India, China, Russia, Brazil, Mexico, South Africa, Turkey, and Indonesia are some of the countries that belong to the pharmerging group.
Improvement in healthcare infrastructure across the globe has led to a surge in healthcare expenditures. Furthermore, rise in incidence of chronic diseases has resulted in growth in healthcare expenditures.
Governments of countries belonging to the pharmerging group are launching reimbursement schemes and policies to reduce the costs of treatment of chronic diseases. They are also conducting extensive research in the fields of immunology, biotechnology, and oncology to develop generic modes of treatment in order to making them accessible for majority of the population in these countries.
However, new entrants may not readily invest in the pharmerging market due to prevalent IP protection issues. This is likely to restrain the pharmerging industry growth during the forecast period.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Healthcare systems in pharmerging countries are extensively promoting generic medications in order to reduce costs.
They are evolving from the strategy of simultaneously balancing quality, access, and cost adages of healthcare to creation of awareness regarding generic therapies through private and public collaboration.
Generic drugs and therapies are available at 20% to 35% discounted prices as compared to their branded counterparts. As per India Brand Equity Foundation’s Indian Pharmaceutical Industry report published in November 2021, the pharmaceutical industry in the country caters to more than 25% of demand for medicines in developed economies of Europe.
Generic medicines have the same contents as their non-generic counterparts. Manufacturers of generic medicines do not invest significantly in marketing and advertising activities. This is one of the primary reasons for their affordability.
The Government of India has launched the ‘Pradhan Mantri Bhartiya Janaushadhi Pariyojana’ (PMBJP) in order to create awareness about generic medicines among the population. It aims to provide generic medicines that cover maximum therapeutic groups.
As per the National Institutes of Health, 60% of the population in India is deprived of regular access to essential medicines.
Thus, rise in demand for generic therapies and drugs across the globe is augmenting the pharmerging market size.
Chronic diseases, also called noncommunicable diseases, have been a cause of concern since the last few years and the population suffering from them is increasing every single year at an alarming rate.
As per the OECD, cardiovascular diseases are the cause of more than 9 million deaths in Asia Pacific.
Rise in awareness about early detection of chronic diseases among the population to facilitate timely treatment is one of the key pharmerging market trends, as it is directly proportional to the time spent in research regarding cost-effective therapies for these ailments.
Need to introduce affordable medications to combat chronic illness at an early stage is thus augmenting the pharmerging market demand.
| Attribute | Detail |
|---|---|
| Leading Region | Asia Pacific |
As per the latest pharmerging market analysis, Asia Pacific held the largest share of the global landscape in 2023. The region is projected to maintain its dominant position during the forecast period. India and China are emerging pharma hubs.
Increase in investments in research and development activities, rise in prevalence of chronic diseases, and growth in urbanization are some of the key factors that are fostering market development in Asia Pacific.
The pharmerging market share of Europe and Latin America is likely to rise in the near future owing to technological advancements in healthcare facilities in these regions.
As per the World Bank, 33% of the population in Latin America is suffering from high blood pressure. Rise in chronic diseases is also fueling market statistics in the region.
Abbott Laboratories, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Company Overview, Novartis AG, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., AstraZeneca, GlaxoSmithKline plc, Lupin, Tata Consultancy Services Ltd., Sun Pharmaceutical Industries Ltd., and Huadong Medicine Co., Ltd. are the leading companies covered in the pharmerging market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 2.1 Bn |
| Market Forecast (Value) in 2034 | US$ 7.1 Bn |
| Growth Rate (CAGR) | 11.6% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 2.1 Bn in 2023
It is projected to grow at a CAGR of 11.6% from 2024 to 2034
Rise in demand for generic therapies and growth in awareness about early detection of chronic diseases
The hospitals segment accounted for the largest share in 2023
Asia Pacific was the dominant region in 2023
Abbott Laboratories, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Company Overview, Novartis AG, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., AstraZeneca, GlaxoSmithKline plc, Lupin, Tata Consultancy Services Ltd., Sun Pharmaceutical Industries Ltd., and Huadong Medicine Co., Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Pharmerging Market
4. Market Overview
4.1. Introduction
4.1.1. Product Type Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Pharmerging Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product Type /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Pharmerging Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2020-2034
6.3.1. Pharmaceuticals
6.3.1.1. Branded Prescription Drugs
6.3.1.2. Generic Drugs
6.3.1.2.1. Branded Generics
6.3.1.2.2. Unbranded Generics
6.3.1.3. OTC Drugs
6.3.2. Healthcare
6.3.2.1. Medical Devices
6.3.2.2. Diagnostic Instruments
6.3.2.3. Others (IT and Record Management)
6.4. Market Attractiveness Analysis, by Product Type
7. Global Pharmerging Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication, 2020-2034
7.3.1. Lifestyle Diseases
7.3.2. Cancer and Autoimmune Diseases
7.3.3. Infectious Diseases
7.3.4. Others
7.4. Market Attractiveness Analysis, by Indication
8. Global Pharmerging Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2020-2034
8.3.1. Hospitals
8.3.2. Clinics
8.3.3. Retail Pharmacies
8.3.4. E-commerce
8.3.5. Drugs Stores
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Pharmerging Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. Europe
9.2.2. Asia Pacific
9.2.3. Latin America
9.2.4. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. Europe Pharmerging Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Product Type, 2020-2034
10.3.1. Pharmaceuticals
10.3.1.1. Branded Prescription Drugs
10.3.1.2. Generic Drugs
10.3.1.2.1. Branded Generics
10.3.1.2.2. Unbranded Generics
10.3.1.3. OTC Drugs
10.3.2. Healthcare
10.3.2.1. Medical Devices
10.3.2.2. Diagnostic Instruments
10.3.2.3. Others (IT and Record Management)
10.4. Market Value Forecast, by Indication, 2020-2034
10.4.1. Lifestyle Diseases
10.4.2. Cancer and Autoimmune Diseases
10.4.3. Infectious Diseases
10.4.4. Others
10.5. Market Value Forecast, by Distribution Channel, 2020-2034
10.5.1. Hospitals
10.5.2. Clinics
10.5.3. Retail Pharmacies
10.5.4. E-commerce
10.5.5. Drugs Stores
10.6. Market Value Forecast, by Country/Sub-region, 2020-2034
10.6.1. Germany
10.6.2. U.K.
10.6.3. France
10.6.4. Italy
10.6.5. Spain
10.6.6. Rest of Europe
10.7. Market Attractiveness Analysis
10.7.1. By Product Type
10.7.2. By Indication
10.7.3. By Distribution Channel
10.7.4. By Country/Sub-region
11. Asia Pacific Pharmerging Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Product Type, 2020-2034
11.3.1. Pharmaceuticals
11.3.1.1. Branded Prescription Drugs
11.3.1.2. Generic Drugs
11.3.1.2.1. Branded Generics
11.3.1.2.2. Unbranded Generics
11.3.1.3. OTC Drugs
11.3.2. Healthcare
11.3.2.1. Medical Devices
11.3.2.2. Diagnostic Instruments
11.3.2.3. Others (IT and Record Management)
11.4. Market Value Forecast, by Indication, 2020-2034
11.4.1. Lifestyle Diseases
11.4.2. Cancer and Autoimmune Diseases
11.4.3. Infectious Diseases
11.4.4. Others
11.5. Market Value Forecast, by Distribution Channel, 2020-2034
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Retail Pharmacies
11.5.4. E-commerce
11.5.5. Drugs Stores
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. China
11.6.2. India
11.6.3. Rest of Asia Pacific
11.7. Market Attractiveness Analysis
11.7.1. By Product Type
11.7.2. By Indication
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Latin America Pharmerging Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Product Type, 2020-2034
12.3.1. Pharmaceuticals
12.3.1.1. Branded Prescription Drugs
12.3.1.2. Generic Drugs
12.3.1.2.1. Branded Generics
12.3.1.2.2. Unbranded Generics
12.3.1.3. OTC Drugs
12.3.2. Healthcare
12.3.2.1. Medical Devices
12.3.2.2. Diagnostic Instruments
12.3.2.3. Others (IT and Record Management)
12.4. Market Value Forecast, by Indication, 2020-2034
12.4.1. Lifestyle Diseases
12.4.2. Cancer and Autoimmune Diseases
12.4.3. Infectious Diseases
12.4.4. Others
12.5. Market Value Forecast, by Distribution Channel, 2020-2034
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Retail Pharmacies
12.5.4. E-commerce
12.5.5. Drugs Stores
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. Brazil
12.6.2. Mexico
12.6.3. Rest of Latin America
12.7. Market Attractiveness Analysis
12.7.1. By Product Type
12.7.2. By Indication
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Middle East & Africa Pharmerging Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Product Type, 2020-2034
13.3.1. Pharmaceuticals
13.3.1.1. Branded Prescription Drugs
13.3.1.2. Generic Drugs
13.3.1.2.1. Branded Generics
13.3.1.2.2. Unbranded Generics
13.3.1.3. OTC Drugs
13.3.2. Healthcare
13.3.2.1. Medical Devices
13.3.2.2. Diagnostic Instruments
13.3.2.3. Others (IT and Record Management)
13.4. Market Value Forecast, by Indication, 2020-2034
13.4.1. Lifestyle Diseases
13.4.2. Cancer and Autoimmune Diseases
13.4.3. Infectious Diseases
13.4.4. Others
13.5. Market Value Forecast, by Distribution Channel, 2020-2034
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Retail Pharmacies
13.5.4. E-commerce
13.5.5. Drugs Stores
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. GCC Countries
13.6.2. South Africa
13.6.3. Rest of Middle East & Africa
13.7. Market Attractiveness Analysis
13.7.1. By Product Type
13.7.2. By Indication
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2023)
14.3. Company Profiles
14.3.1. Abbott Laboratories
14.3.1.1. Company Overview
14.3.1.2. Product Type Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Koninklijke Philips N.V.
14.3.2.1. Company Overview
14.3.2.2. Product Type Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. F. Hoffmann-La Roche Ltd.
14.3.3.1. Company Overview
14.3.3.2. Product Type Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Merck & Co., Inc.
14.3.4.1. Company Overview
14.3.4.2. Product Type Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Novartis AG
14.3.5.1. Company Overview
14.3.5.2. Product Type Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. Johnson & Johnson
14.3.6.1. Company Overview
14.3.6.2. Product Type Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. Teva Pharmaceutical Industries Ltd.
14.3.7.1. Company Overview
14.3.7.2. Product Type Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. AstraZeneca
14.3.8.1. Company Overview
14.3.8.2. Product Type Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. GlaxoSmithKline plc
14.3.9.1. Company Overview
14.3.9.2. Product Type Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Lupin
14.3.10.1. Company Overview
14.3.10.2. Product Type Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview
14.3.11. Tata Consultancy Services Ltd.
14.3.11.1. Company Overview
14.3.11.2. Product Type Portfolio
14.3.11.3. SWOT Analysis
14.3.11.4. Financial Overview
14.3.11.5. Strategic Overview
14.3.12. Sun Pharmaceutical Industries Ltd.
14.3.12.1. Company Overview
14.3.12.2. Product Type Portfolio
14.3.12.3. SWOT Analysis
14.3.12.4. Financial Overview
14.3.12.5. Strategic Overview
14.3.13. Huadong Medicine Co., Ltd.
14.3.13.1. Company Overview
14.3.13.2. Product Type Portfolio
14.3.13.3. SWOT Analysis
14.3.13.4. Financial Overview
14.3.13.5. Strategic Overview
List of Tables
Table 01: Global Pharmerging Market Size (US$ Mn) Forecast, by Product Type, 2020-2034
Table 02: Global Pharmerging Market Size (US$ Mn) Forecast, by Indication, 2020-2034
Table 03: Global Pharmerging Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 04: Global Pharmerging Market Size (US$ Mn) Forecast, by Region, 2020-2034
Table 05: Europe Pharmerging Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 06: Europe Pharmerging Market Size (US$ Mn) Forecast, by Product Type, 2020-2034
Table 07: Europe Pharmerging Market Size (US$ Mn) Forecast, by Indication, 2020-2034
Table 08: Europe Pharmerging Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 09: Asia Pacific Pharmerging Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 10: Asia Pacific Pharmerging Market Size (US$ Mn) Forecast, by Product Type, 2020-2034
Table 11: Asia Pacific Pharmerging Market Size (US$ Mn) Forecast, by Indication, 2020-2034
Table 12: Asia Pacific Pharmerging Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 13: Latin America Pharmerging Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Latin America Pharmerging Market Size (US$ Mn) Forecast, by Product Type, 2020-2034
Table 15: Latin America Pharmerging Market Size (US$ Mn) Forecast, by Indication, 2020-2034
Table 16: Latin America Pharmerging Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
Table 17: Middle East & Africa Pharmerging Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 18: Middle East & Africa Pharmerging Market Size (US$ Mn) Forecast, by Product Type, 2020-2034
Table 19: Middle East & Africa Pharmerging Market Size (US$ Mn) Forecast, by Indication, 2020-2034
Table 20: Middle East & Africa Pharmerging Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
List of Figures
Figure 01: Global Pharmerging Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Pharmerging Market Revenue (US$ Mn), by Product Type, 2023
Figure 03: Global Pharmerging Market Value Share, by Product Type, 2023
Figure 04: Global Pharmerging Market Revenue (US$ Mn), by Indication, 2023
Figure 05: Global Pharmerging Market Value Share, by Indication, 2023
Figure 06: Global Pharmerging Market Revenue (US$ Mn), by Distribution Channel, 2023
Figure 07: Global Pharmerging Market Value Share, by Distribution Channel, 2023
Figure 08: Global Pharmerging Market Value Share, by Region, 2023
Figure 09: Global Pharmerging Market Value (US$ Mn) Forecast, 2020-2034
Figure 10: Global Pharmerging Market Value Share Analysis, by Product Type, 2023 and 2034
Figure 11: Global Pharmerging Market Attractiveness Analysis, by Region, 2024-2034
Figure 12: Global Pharmerging Market Value Share Analysis, by Indication, 2023 and 2034
Figure 13: Global Pharmerging Market Attractiveness Analysis, by Indication, 2024-2034
Figure 14: Pharmerging Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 15: Global Pharmerging Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 16: Global Pharmerging Market Value Share Analysis, by Region, 2023 and 2034
Figure 17: Global Pharmerging Market Attractiveness Analysis, by Region, 2024-2034
Figure 18: Europe Pharmerging Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 19: Europe Pharmerging Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 20: Europe Pharmerging Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 21: Europe Pharmerging Market Value Share Analysis, by Product Type, 2023 and 2034
Figure 22: Europe Pharmerging Market Value Share Analysis, by Indication, 2023 and 2034
Figure 23: Europe Pharmerging Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 24: Europe Pharmerging Market Attractiveness Analysis, by Region, 2024-2034
Figure 25: Europe Pharmerging Market Attractiveness Analysis, by Indication, 2024-2034
Figure 26: Europe Pharmerging Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 27: Asia Pacific Pharmerging Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 28: Asia Pacific Pharmerging Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 29: Asia Pacific Pharmerging Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 30: Asia Pacific Pharmerging Market Value Share Analysis, by Product Type, 2023 and 2034
Figure 31: Asia Pacific Pharmerging Market Value Share Analysis, by Indication, 2023 and 2034
Figure 32: Asia Pacific Pharmerging Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 33: Asia Pacific Pharmerging Market Attractiveness Analysis, by Region, 2024-2034
Figure 34: Asia Pacific Pharmerging Market Attractiveness Analysis, by Indication, 2024-2034
Figure 35: Asia Pacific Pharmerging Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 36: Latin America Pharmerging Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 37: Latin America Pharmerging Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 38: Latin America Pharmerging Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 39: Latin America Pharmerging Market Value Share Analysis, by Product Type, 2023 and 2034
Figure 40: Latin America Pharmerging Market Value Share Analysis, by Indication, 2023 and 2034
Figure 41: Latin America Pharmerging Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 42: Latin America Pharmerging Market Attractiveness Analysis, by Region, 2024-2034
Figure 43: Latin America Pharmerging Market Attractiveness Analysis, by Indication, 2024-2034
Figure 44: Latin America Pharmerging Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 45: Middle East & Africa Pharmerging Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 46: Middle East & Africa Pharmerging Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 47: Middle East & Africa Pharmerging Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 48: Middle East & Africa Pharmerging Market Value Share Analysis, by Product Type, 2023 and 2034
Figure 49: Middle East & Africa Pharmerging Market Value Share Analysis, by Indication, 2023 and 2034
Figure 50: Middle East & Africa Pharmerging Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 51: Middle East & Africa Pharmerging Market Attractiveness Analysis, by Region, 2024-2034
Figure 52: Middle East & Africa Pharmerging Market Attractiveness Analysis, by Indication, 2024-2034
Figure 53: Middle East & Africa Pharmerging Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Pharmerging Market
*86 figures and 60 tables includes